This Article Full Text Full Text (PDF) CME: Take the course for this article: Circulation: March 6, 2007, Volume 115, Number 9 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hueb, W. Articles by Ramires, J. A.F. Search for Related Content PubMed PubMed Citation Articles by Hueb, W. Articles by Ramires, J. A.F. Related Collections Catheter-based coronary interventions: stents CV surgery: coronary artery disease Related Article

(Circulation. 2007;115:1082-1089.)
© 2007 American Heart Association, Inc.

Heart Disease in Latin America

Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS II)

A Randomized Controlled Clinical Trial of 3 Therapeutic Strategies for Multivessel Coronary Artery Disease

Whady Hueb, MD, PhD; Neuza Helena Lopes, MD, PhD; Bernard J. Gersh, MB, ChB, DPhil; Paulo Soares, MD, PhD; Luiz A.C. Machado, MD, PhD; Fabio B. Jatene, MD, PhD; Sergio A. Oliveira, MD, PhD; Jose A.F. Ramires, MD, PhD

From the Heart Institute of the University of São Paulo (W.H., N.H.L., P.S., L.A.C.M., F.B.J., S.A.O., J.A.F.R.), São Paulo, Brazil, and the Mayo Clinic (B.J.G.), Rochester, Minn.

Reprint requests to Whady Hueb, MD, PhD, Av Dr Eneas de Carvalho Aguiar 44, AB Sala 114 Cerqueira César, São Paulo-SP/Brazil 05403–000. E-mail whady.hueb{at}incor.usp.br or mass@incor.usp.br

Received August 4, 2006; accepted November 10, 2006.

Background— Despite routine use of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI), no conclusive evidence exists that either modality is superior to medical therapy (MT) alone for treating multivessel coronary artery disease with stable angina and preserved ventricular function.

Methods and Results— The primary end points were total mortality, Q-wave myocardial infarction, or refractory angina requiring revascularization. The study comprised 611 patients randomly assigned to undergo CABG (n=203), PCI (n=205), or MT (n=203). At the 5-year follow-up, the primary end points occurred in 21.2% of patients who underwent CABG compared with 32.7% treated with PCI and 36% receiving MT alone (P=0.0026). No statistical differences were observed in overall mortality among the 3 groups. In addition, 9.4% of MT and 11.2% of PCI patients underwent repeat revascularization procedures compared with 3.9% of CABG patients (P=0.021). Moreover, 15.3%, 11.2%, and 8.3% of patients experienced nonfatal myocardial infarction in the MT, PCI, and CABG groups, respectively (P<0.001). The pairwise treatment comparisons of the primary end points showed no difference between PCI and MT (relative risk, 0.93; 95% confidence interval, 0.67 to 1.30) and a significant protective effect of CABG compared with MT (relative risk, 0.53; 95% confidence interval, 0.36 to 0.77).

Conclusions— All 3 treatment regimens yielded comparable, relatively low rates of death. MT was associated with an incidence of long-term events and rate of additional revascularization similar to those for PCI. CABG was superior to MT in terms of the primary end points, reaching a significant 44% reduction in primary end points at the 5-year follow-up of patients with stable multivessel coronary artery disease.

Key Words: angina • angiography • bypass • coronary disease • follow-up studies • prognosis • revascularization

Related Article:

Issue Highlights
Circulation 2007 115: 1059. [Full Text]

This article has been cited by other articles:

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF]

				J. Sanz, P. R. Moreno, and V. Fuster The year in atherothrombosis. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 944 - 955. [Full Text] [PDF]

				G. A. Diamond and S. Kaul COURAGE Under Fire: On the Management of Stable Coronary Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1604 - 1609. [Abstract] [Full Text] [PDF]

				D. J. Kereiakes, P. S. Teirstein, I. J. Sarembock, D. R. Holmes Jr, M. W. Krucoff, W. W. O'Neill, R. Waksman, D. O. Williams, J. J. Popma, M. Buchbinder, et al. The Truth and Consequences of the COURAGE Trial J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1598 - 1603. [Abstract] [Full Text] [PDF]

				R. Lehman Evidently... Evid. Based Med., October 1, 2007; 12(5): 135 - 135. [Full Text] [PDF]

				Other articles noted Evid. Based Med., October 1, 2007; 12(5): 159 - 160. [Full Text] [PDF]

				T. Gershlick and M. Thomas PCI or CABG: which patients and at what cost? Heart, October 1, 2007; 93(10): 1188 - 1190. [Full Text] [PDF]

				N. Beohar, C. J. Davidson, K. E. Kip, H. A. Vlachos, and D. O. Williams Off-Label Use of Drug-Eluting Stents Reply JAMA, August 22, 2007; 298(8): 859 - 860. [Full Text] [PDF]

				Treatment Strategies for Multivessel CAD, Compared Journal Watch Cardiology, May 9, 2007; 2007(509): 5 - 5. [Full Text]

				S. B. King III Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS-II): Prologue to COURAGE Circulation, March 6, 2007; 115(9): 1064 - 1066. [Full Text] [PDF]